Efficacy of Low Molecular Weight Heparin in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease Receiving Ventilatory Support

References

• Decramer M, Janssens W, Miravittles M. Chronic obstructive pulmonary disease. Seminar. Lancet 2012; 379:1341–1351.
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Buist AS, Calverley PM, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163:1256–1276.
   PubMedGoogle Scholar
• Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60:925–931.
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang TT, Ye J. Analysis of risk factors for hospital mortality in patients with chronic obstructive pulmonary diseases requiring invasive mechanical ventilation. Chin Med J (Engl) 2007; 120:287–293.
   PubMed Web of Science ®Google Scholar
• Garcia-Aymerich J, Farrero E, Felez MA, Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 2003; 58:100–105.
   PubMed Web of Science ®Google Scholar
• Casu B. Structure of heparin and heparin fragments. Ann NY Acad Sci 1989; 556:1–17.
   PubMed Web of Science ®Google Scholar
• Baglin T, Barrowcliffe TW, Cohen A, Guidelines on the use and monitoring of heparin. Br J Haematol 2006; 33:19–34.
   Google Scholar
• Ludwig RJ. Therapeutic use of heparin beyond anticoagulation. Curr Drug Discov Technol 2009; 6:281–289.
   PubMedGoogle Scholar
• Akyol C, Ozis E, Cakmak A, Nadroparine blunts lipopolysaccharide-induced hypothermia and behavioral depression in mice. J Invest Surg 2008; 21:311–317.
   PubMed Web of Science ®Google Scholar
• Page CP. One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanism by beta 2-agonists. Lancet 1991; 337:717–720.
   PubMed Web of Science ®Google Scholar
• Chande N, MacDonald JK, Wang JJ, Unfractionated or low molecular weight heparin for induction of remission in ulcerative colitis: a Cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials. Inflamm Bowel Dis 2011 Sep; 17(9):1979–1986.
   PubMed Web of Science ®Google Scholar
• Lever R, Page CP.Non-anticoagulant effects of heparin: an overview. Hand Exp Pharmacol 2012; 207:281–305.
   PubMedGoogle Scholar
• Jennewein C, Paulus P, Zacharowski K. Linking inflammation and coagulation: novel drug targets to treat organ ischemia. Curr Opin Anaesthesiol 2011 Aug; 24(4):375–380.
   PubMed Web of Science ®Google Scholar
• Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res 2008; 122:743–752.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis,management,and prevention of chronic obstructive pulmonary disease. 2009.
   Google Scholar
• National Clinical Guideline Centre (UK). Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. 2010.
   Google Scholar
• Mannino DM, Braman S. The epidemiology and economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007; 4:502–506.
   PubMedGoogle Scholar
• Wouters EF, Reynaert NL, Dentener MA, Systemic and local inflammation in asthma and chronic obstructive pulmonary disease: is there a connection? Proc Am Thorac Soc 2009; 6:638–637.
   PubMedGoogle Scholar
• Dev D, Wallace E, Sankaran R, Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med 1998; 92:664–667.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Seemungal TA, MacCallum PK, Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000; 84:210–215.
   PubMed Web of Science ®Google Scholar
• Undas A, Kaczmarek P, Sladek K, Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment. Thromb Haemost 2009; 102:1176–1182.
   PubMed Web of Science ®Google Scholar
• Dentener MA, Creutzberg EC, Schols AM, Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax 2001; 56:721–726.
   PubMed Web of Science ®Google Scholar
• Cai C, Zhang HY, Le JJ, Inflammatory airway features and hypothalamic-pituitary-adrenal axis function in asthmatic rats combined with chronic obstructive pulmonary disease. Chin Med J(Engl) 2010; 123:1720–1726.
   PubMed Web of Science ®Google Scholar
• Wouters EF. Chronic obstructive pulmonary disease. 5: systemic effects of COPD. Thorax 2002; 57:1067–1070.
   PubMed Web of Science ®Google Scholar
• Miao JB, Hou SC, Li H, Clinical study of inflammatory factors in sputum induced early after lung volume reduction surgery. Chin Med J (Engl) 2008; 121:1796–1799.
   PubMed Web of Science ®Google Scholar
• Mousa SA. Heparin and low-molecular weight heparins in thrombosis and beyond. Methods Mol Biol 2010; 663:109–132.
   PubMedGoogle Scholar
• Hiebert LM, Liu JM. Heparin protects cultured arterial endothelial cells from damage by toxic oxygen metabolites. Atherosclerosis 1990; 83:47–51.
   PubMed Web of Science ®Google Scholar
• Derhaschnig U, Pernerstorfer T, Knechtelsdorfer M, Evaluation of antiinflammatory and antiadhesive effects of heparins in human endotoxemia. Crit Care Med 2003; 31:1108–1112.
   PubMed Web of Science ®Google Scholar
• Lantz M, Thysell H, Nilsson E, On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J Clin Invest 1991; 88:2026–2031.
   PubMed Web of Science ®Google Scholar
• Nelson RM, Cecconi O, Roberts WG,et al. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993; 82:3253–3258.
   PubMed Web of Science ®Google Scholar
• Tyrell DJ, Kilfeather S, Page CP. Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci 1995; 16:198–204.
   PubMed Web of Science ®Google Scholar
• Shin K, Nigrovic PA, Crish J, Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes. J Immunol 2009; 182:647–656.
   PubMed Web of Science ®Google Scholar
• Kanabar V, Page CP, Simcock DE, Heparin and structurally related polymers attenuate eotaxin-1 (CCL11) release from human airway smooth muscle. Br J Pharmacol 2008; 154:833–842.
   PubMed Web of Science ®Google Scholar
• Dotan I, Hallak A, Arber N, Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial. Dig Dis Sci 2001; 46:2239–2244.
   PubMed Web of Science ®Google Scholar
• Torkvist L, Thorlacius H, Sjoqvist U, Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment Pharmacol Ther 1999; 13:1323–1328.
   PubMed Web of Science ®Google Scholar
• Alessandri C, Basili S, Violi F, Hypercoagulability state in patients with chronic obstructive pulmonary disease. Chronic Obstructive Bronchitis and Haemostasis Group. Thromb Haemost 1994; 72:343–346.
   PubMed Web of Science ®Google Scholar
• Brown RA, Allegra L, Matera MG, Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination. Pulm Pharmacol Ther 2006; 19:419–424.
   PubMed Web of Science ®Google Scholar
• Shi X, Li H. Anticoagulation therapy in patients with chronic obstructive pulmonary disease in the acute exacerbation stage. Exp Ther Med 2013; 5:1367–1370.
   Web of Science ®Google Scholar